Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Argus' Stephen Biggar initiated coverage of Sanofi SA (ADR) (NYSE:SNY) with a Buy rating and $50 price target as the company has moved past a challenging period.
According to Biggar, Sanofi has suffered through a period in which two of its best selling drugs, Lantus (diabetes) and Plavix (prevention of blood clots) have seen their patents expire. The company also had to deal with legal issues, including a court ruling in which its cholesterol-lowering therapy Praluent infringed on patents held by rival pharmaceutical firm Amgen, Inc. (NASDAQ:AMGN).
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Amgen 'Largely Moved Past' Prior Headwinds
Biggar now believes Amgen has "largely moved past" these events and investors can look forward to the company benefiting from the strong demand for its multiple sclerosis drugs and management's cost-cutting initiatives.
Biggar added that Amgen also boasts a strong pipeline of new drugs, including Toujeo, which is a next-generation insulin product. Other notable therapies in the pipeline include dipilumab for atopic dermatitis and other inflammatory conditions.
Valuation Is Attractive
Biggar further noted that Sanofi's stock is trading at 15.4x his 2017 earnings per ADS forecast which is short of the average multiple of 16.2x for S&P 500 Pharma companies. The analyst believes the stock shouldn't trade at a discount to the group average, rather it should trade at a slight premium given the company's positioning for growth.
Sanofi also pays investors a sustainable dividend which has been raised over the past 23 years and currently yields around 3.5 percent.
See also:
Argus Initiates Bioverativ With Hold
Here Are The 4 Commercial Launches In 2017 That Earned Tesaro A Buy Rating At Argus
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.